A phase 1 study of STRO-001, an anti-CD74 antibody drug conjugate, in patients with advanced B-cell malignancies

In August 2018, LLS partnered with Sutro Biopharma to support "A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies."

Sutro Biopharma is a clinical-stage drug discovery, development and manufacturing company that uses precise protein engineering and rational design to advance next-generation oncology therapeutics.

STRO-001 is a CD74-targeting antibody-drug conjugate (ADC) currently being investigated in a Phase 1 clinical trial of patients with advanced B-cell malignancies, including multiple myeloma and non-Hodgkin lymphoma (NCT03424603). STRO-001 is a new generation of ADC with more efficient homogeneous ADC design, which has the potential to minimize unwanted toxicity and improve clinical impact over prior technologies.